New daily shot could curb appetite in obesity
Disease control
Completed
This completed Phase 2 trial tested whether a daily injection of ROSE-010, a GLP-1 analogue, can reduce appetite and food intake in 40 overweight or obese women. Participants received either a low or high dose of ROSE-010 or a placebo, and researchers measured how much they ate a…
Phase: PHASE2 • Sponsor: Rose Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC